Indeed, one study that examined survival among HER2+ MBC patients with BMs who were similarly treated at a highly specialized cancer center in the US in a more recent timeframe (through 2022) found survival to be ~26 months, which is more similar to our results [28]. The gene discussed is ERBB2; the disease is cancer.